STEX underwent a dramatic operational transformation, with revenue, R&D spending, and inventory all declining substantially, while the share structure expanded dramatically from 24.2M to 97.7M shares outstanding.
The company appears to have shifted from BioSig Technologies to Streamex Corp., representing a fundamental business transformation rather than organic growth or decline. The massive increase in share count combined with the introduction of exchangeable shares suggests a significant corporate restructuring, merger, or acquisition that completely altered the entity's profile.
The financial metrics reflect a dramatic operational contraction, with revenue, gross profit, and R&D expenses all falling by over 90%, while inventory declined substantially. However, these changes appear to reflect a corporate transformation from BioSig Technologies to Streamex Corp. rather than operational deterioration of the same business. The scale of decline across all operational metrics, combined with the fundamental change in corporate identity and share structure, suggests investors are looking at an entirely different entity post-transaction.
R&D spending cut 96.3% — could signal cost discipline or concerning reduction in innovation investment.
Revenue declined 93.7% — significant demand weakness or market share loss warrants investigation.
Gross margin compression — rising input costs, pricing pressure, or unfavorable product mix shift.
Inventory drawn down 82.1% — strong sell-through or deliberate destocking; watch for supply constraints.
See what changed in your portfolio's filings
500+ US-listed companies analyzed. Language delta, financial analysis, instant signal scoring.
Try Tracenotes free →